Glycan Profiling for Therapeutic Antibodies: What to Measure and Why

Glycosylation is one of the most functionally significant post-translational modifications in therapeutic antibody production. For IgG-based biologics, the N-linked glycan at Asn-297 in the Fc region is not a byproduct of expression — it is an integral determinant of how your drug behaves in the body. Understanding what to measure, which analytical platform to use, and how to control glycan profile through your manufacturing process is essential for both regulatory compliance and clinical success.

Why Glycosylation Is a Critical Quality Attribute

N-linked glycosylation at Asn-297 in the Fc region of IgG antibodies directly modulates effector functions including ADCC, CDC, and ADCP, influences Fc receptor binding affinity, affects half-life, and can drive immunogenicity. The glycan profile of your drug substance is therefore a critical quality attribute (CQA) that must be characterized, controlled, and reported throughout development and into the clinic.

Regulatory guidance documents from FDA, EMA, and ICH — particularly ICH Q6B — require that manufacturers demonstrate understanding of how manufacturing process changes affect glycosylation and that they maintain control through defined specifications at release and stability.

Glycosylation is not a passive modification. It is a functional determinant of your drug's mechanism of action and safety profile — and regulators treat it accordingly.

What to Measure: The Core Glycan Species

For a standard IgG1 therapeutic antibody, the glycan species of primary regulatory and functional relevance are:

• G0F, G1F, G2F — the core fucosylated complex-type bi-antennary species that make up 60–90% of most CHO-derived antibody glycans
• Afucosylated species (G0, G1, G2) — which significantly enhance FcγRIIIa binding and ADCC activity
• High mannose species (Man5–Man9) — which influence clearance rate and can be elevated by certain cell culture conditions
• Sialylated species (SA-G1F, SA-G2F) — which affect anti-inflammatory properties and serum half-life
• G0 (non-galactosylated) fraction — which correlates with Fc-mediated effector function modulation

Analytical Methods: 2-AB Labeling, LC-MS, and Their Applications

The most common platform for N-glycan profiling in a development and GMP release context is fluorescent labeling of released glycans with 2-aminobenzamide (2-AB) followed by normal-phase HPLC or UHPLC with fluorescence detection. This method is robust, reproducible, and well-suited to batch release because it offers quantitative relative abundance for all major glycan species in a single 45–60 minute run.

A qualified 2-AB HILIC method with a reference glycan standard ladder provides retention time-based identification with ≥1% quantitation precision for major species. For higher resolution structural confirmation and detection of low-abundance or unusual glycans, LC-MS/MS using an Orbitrap or Q-TOF platform is the gold standard.

Controlling Glycosylation Through the Manufacturing Process

Glycan profile is sensitive to a wide range of upstream process parameters. Understanding these relationships during process development — and capturing them in your DoE-based design space — is what allows glycan profile to be controlled by process parameters, not just monitored at release.

• Manganese concentration is the most potent modulator of galactosylation — supplementation at 0.1–0.5 µM typically increases G1F and G2F species by 10–20 percentage points
• Dissolved oxygen below 20% saturation elevates high mannose species
• Glucose depletion in fed-batch culture increases fucosylation variability
• Temperature shifts reducing culture temperature from 37°C to 33–34°C can alter the G0F/G1F ratio

Glycan control is not a late-stage activity. The decisions made during cell line selection, media formulation, and process development collectively determine your glycan profile. Characterizing these relationships early — and building them into your design space — creates a product quality story that regulators can follow from development through the clinic.